Objectives. Salivary cystatin S is a defence protein mainly produced by submandibular glands and involved in innate oral immunity. This study aimed to verify whether cystatin S was diversely expressed in different disease subsets of primary Sjogren's syndrome (pSS) patients, defined on the basis of salivary flow [unstimulated salivary flow rate (USFR)], minor salivary gland (MSG) focus score and submandibular gland ultrasonography abnormalities. We also evaluated miR-126 and miR-335-5p expression in MSG biopsies to verify whether an aberrant regulation of cystatin S at the glandular level may influence its salivary expression.
and intensity of the infiltrate in minor salivary glands (MSGs) and may display great variability in terms of salivary flow rate, showing a relatively weak inverse correlation between MSG focus score and salivary flow rate [3] . Lately, great efforts have been made pursuing research for novel and reliable pSS phenotypic and genotypic biomarkers that are able to distinguish between the different disease subsets by applying emerging complementary proteomics and molecular biology techniques to the analysis of patients' saliva [46] . Since pSS is characterized by chronic inflammation of the salivary glands, saliva seems a promising biofluid able to closely reflect the underlying local pSS exocrinopathy. In addition, saliva can be non-invasively and repeatedly collected without any discomfort to patients [79] .
Despite some encouraging preliminary findings, a number of drawbacks, including intersubject variability of whole saliva, prevented scientists from translating proteomics results into clinical settings, highlighting the crucial need for validation studies able to identify reliable biomarkers for pSS and specific disease subsets.
To date, several candidate biomarkers for pSS have been proposed, including numerous defence proteins like salivary immunoglobulins; chaperokines; bactericidal/permeability increasing protein; bactericidal/permeability increasinglike proteins; palate, lung and nasal epithelial clone proteins; cationic peptides; lysozyme; prolin-rich proteins; mucins; statherin and cystatins [4, 1015] . Recently we demonstrated that a secretory acinar protein, gross cystic disease fluid protein-15/prolactin-inducible protein, was significantly decreased in pSS and may have a role in the diagnostic algorithm of the disease, being able to discriminate between patients with pSS and subjects with non-immune sicca syndrome [16] .
In this article we focused our attention on cystatin S, a salivary protein that has appeared of particular interest in pSS. Cystatins are cysteine protease inhibitors expressed in numerous cell types and regulate a number of physiological processes [17] . Five cystatins have been extensively studied: cystatin A, cystatin B, cystatin C, cystatin S and cystatin M. Their aberrant regulation has been described as occurring in a number of diseases, including cancer, autoimmunity and certain neurodegenerative disorders [11, 18, 19] . Proteomics studies have shown that cystatin S is differently expressed in whole saliva of pSS patients with respect to healthy volunteers (HVs), suggesting that these proteins may have a direct role in innate and acquired oral immunity [4, 2023] . More specifically, cystatin S inhibits the action of endogenous, bacterial and parasitic protozoan proteases, binds bacterial lipopolysaccharides and seems to exert direct immunomodulatory effects [24] .
The aim of this study was to validate previous proteomics findings on the expression of salivary cystatin S in patients with pSS to verify whether cystatin S could be considered an early biomarker for this syndrome. First, we wanted to understand whether cystatin S might have a role in the identification of pSS patient subgroups when stratified on the basis of their salivary flow rate and MSG focus score. Second, since cystatin S is mainly produced by submandibular glands [25] and early pSS seems to be characterized by a more prominent involvement of submandibular glands [26] , we also explored whether pSS patients with pathological ultrasonography findings in their submandibular glands presented a lower expression of cystatin S. Finally, we investigated the expression of cystatin S in MSG biopsies of pSS patients in order to verify whether an aberrant regulation of cystatin S at the glandular level may be involved in its phenotypic expression in whole saliva.
Methods
Study population, sample collection and processing This study was performed at the University of Pisa, a referral centre for pSS in Italy. The local independent ethics committee, Comitato Etico Area Vasta Nord Ovest Sezione Autonoma del Comitato Etico Regionale per la Sperimentazione Clinica, approved this study and all patients signed written consent forms. Unstimulated whole salivary samples were collected according to a standard procedure [16] from patients with pSS [27] . Submandibular and parotid gland flow rates were not individually collected. Twenty age-and sex-matched HVs were included as controls. Briefly, salivary samples were collected between 9 and 11 A.M. from patients who had refrained from eating or drinking for at least 2 h. A salivary flow rate 41.5 ml/15 min was considered pathological [27] . Five pSS patients were followed over time and their salivary flow collected at time 0 and at time 12 months in order to measure any variation in cystatin S in relation with variation of the salivary flow rate. Finally, all the patients underwent a complete ultrasonography assessment of their major salivary glands. Salivary gland ultrasonography (SGUS) was performed using a Logic 9 system (General Electric Medical Systems, Milwaukee,WI, USA). A simplified scoring system based on parenchymal inhomogeneity, ranging from grade 0 (normal) to grade 4 (grossly inhomogeneous), was adopted to assess major salivary gland involvement at the ultrasonography. A SGUS score 52 was considered as pathological [2831] .
After collection and salivary flow rate determination, in order to minimize degradation of the proteins, the samples were immediately processed and kept on ice. Samples were centrifuged at 13 000 g for 20 min at 4 C to remove debris and cells and protein amounts of resulting supernatants were determined using Protein Assay dye reagent (Bio-Rad, Richmond, CA, USA). Aliquots of the samples were stored at À80 C until analysis.
MSG biopsies for molecular analysis
MSGs were obtained as part of routine diagnostic procedures in pSS patients. In all cases the MSG specimens from each subject were divided into two samples: a sample was fixed in neutral buffered formalin, paraffin-embedded and haematoxylin and eosin stained for the focus score assessment, while the other was snap frozen and stored at À80 C. The frozen sample was employed for the real-time PCR analysis. More specifically, for molecular analysis we selected the MSG biopsies of 10/40 pSS patients with a focus score >3. Five pSS patients presented a preserved salivary flow (i.e. high salivary flow) and five patients presented a salivary flow 41.5 ml/15 min (i.e. low salivary flow). Five further biopsies from patients with idiopathic sicca syndrome were used as controls.
Western blot analysis
We employed a stain-free technology, which has recently been demonstrated to be a more reliable, robust and sensitive normalization tool for western blot experiments when compared with traditional housekeeping protein normalization [32] . More specifically, one-dimensional SDS-electrophoresis was first performed. Aliquots of all saliva samples (30 mg of total protein) were treated with Laemmli buffer and heated at 100 C for 5 min, loaded on 420% Mini-PROTEAN TGX Stain-Free precast gels (#456-8093; Bio-Rad, Hercules, CA, USA) and run for 30 min at 200 V according to manufacturer's instructions. After electrophoresis, stain-free gels underwent ultraviolet activation in order to assess protein transfer after blotting (total protein volume acquired from each lane by ChemiDoc, Bio-Rad). Western blot was subsequently performed using a commercial anti-cystatin S antibody (ab151771; Abcam, Cambridge, UK) as the primary antibody. The chemiluminescence expressed in terms of the volume of specific immunoreactive bands was determined (ChemiDoc, Bio-Rad) and normalized to the previously acquired total protein volume. Each value was then normalized on an internal control sample (the same for every gel) treated in the same experimental conditions in order to compare samples that had run in different gels.
Real-time PCR
Total RNA was extracted using the miRNeasy Mini Kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. Reverse transcription was performed using the High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific, Waltham, MA, USA), according to the manufacturer's instructions, to obtain cDNA. cDNA was subsequently analysed by quantitative PCR (qPCR) in a 20 ml total volume of a mixture containing 1X TaqMan Universal MasterMix II (Thermo Fisher Scientific), 900 nM of each primer and 180 nM of probe. The TaqMan gene assay (Applied Biosystems, Waltham, MA, USA) for CST4 (Hs00605451_mH) was used. The samples were normalized according to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA (Hs99999905_m1) levels. Reverse transcription for miRNAs was performed using the TaqMan MicroRNA Reverse Transcription Kit with specific miRNA primers (Applied Biosystems). TaqMan miRNA assays (Applied Biosystems) were used for relative quantification of the mature miR-335-5p (000546) and miR-126 (002228) expression levels. U6 snRNA (001973) was used to normalize the results. An Applied Biosystems 7900HT Fast RT-PCR System was used for measurements. The expression fold change was calculated by the 2
ÀÁÁCT method for each of the reference genes.
All test samples were run in duplicate and template-negative reactions served as controls.
Statistical analysis
Continuous data were expressed as mean (S.D.). Statistical analyses of the results were carried out using the chi-square test and the MannWhitney test. Spearman's rank correlation coefficient was employed in order to correlate subjects' clinical parameters with the normalized values of band intensity from western blot and the log of relative quantification values from qPCR. In addition, a semi-quantification of the normalized values of cystatin S band intensity from western blot (normal or low) was also obtained using the minimum value of cystatin S expression level of normal controls as a cutoff point. P-values <0.05 were considered significant. SPSS version 16.0 (SPSS, Chicago, IL, USA) was used for statistical analysis. Real-time RT-PCR data processing and analysis were conducted using tools from Microsoft Excel and Prism GraphPad version 5.0d (GraphPad Software, La Jolla, CA, USA). The statistical significance of observed differences among different experimental groups was calculated using a two-tailed unpaired Student's t-test. P-values <0.05 were considered to be statistically significant.
Results
Salivary cystatin S is reduced in whole saliva of patients with pSS
Forty women affected by pSS were included in this study.
Twenty age-and sex-matched HVs were enrolled as controls. Fig. 1A , whereas Fig. 1B shows a representative western blot of cystatin S expression in patients and HVs. We also assessed salivary cystatin S levels in five subjects with idiopathic sicca syndrome and found that cystatin S was significantly reduced in pSS with respect to idiopathic sicca syndrome controls (pSS vs sicca: mean cystatin S 0.53 (S.D. 0.36) vs 1.43 (0.74), P < 0.001]. MSG biopsy samples from these five idiopathic sicca syndrome controls were used for the miRNA experiments (see below).
Correlation between salivary cystatin S and salivary flow rate
We observed a positive correlation between salivary cystatin S and unstimulated salivary flow rate (USFR) (r = 0.410, P = 0.02) in patients with pSS. In addition, pSS patients with an MSG focus score 53 presented lower levels of cystatin S when compared with patients with an MSG focus score <3 [0.18 (S.D. 0.76) vs 0.68 (0.19), P < 0.001] and we did not find a significant correlation between MSG focus score and cystatin S level or USFR (Supplementary Figs S1 and S2, available at Rheumatology Online). To focus attention on the relationship between unstimulated salivary flow and cystatin S, we limited the analysis to pSS patients with an MSG focus score 53. In these patients we found an even stronger positive correlation between cystatin S and salivary flow (r = 0.751, P = 0.01). The scatter graph shown in Fig.  2 represents the correlation between cystatin S and USFR in pSS patients with a high focus score. In order to confirm the relationship between USFR and cystatin S, in five pSS patients whole saliva was collected twice during the follow-up. In these patients we found a strong correlation between the change in cystatin S and the change in USFR (r = 0.94, P < 0.001) (Fig. 3) . To verify the impact of disease duration on cystatin S levels we also analysed any eventual correlation between salivary cystatin S levels and disease duration. We did not find any statistically significant correlation (r = À0.08, P = 0.62). However, it should be noted that none of our patients was enrolled at the diagnosis and that it remains challenging to define exactly the duration of pSS since symptoms may develop insidiously, with the diagnosis often not considered for several years.
Correlation between salivary cystatin S and pathological findings in submandibular glands at SGUS
We analysed salivary expression of cystatin S in pSS patients stratified according to the presence/absence of abnormal findings at the SGUS. More specifically, since cystatin S seems to be produced mainly by submandibular glands rather than by parotid glands, we assigned separate US scores to submandibular glands and parotid glands. Fifteen patients had an SGUS score 52 in the submandibular glands and 22 patients had an SGUS score 52 in the parotid glands. As shown in Fig. 4A and B, we found that the expression of cystatin S was significantly reduced in patients with abnormal findings in submandibular glands [cystatin S: mean 0.35 (S.D. 0.06) vs 0.70 (0.08), P < 0.001], whereas no differences were observed when patients were stratified according to the presence/absence of an SGUS score >2 in the parotid glands.
Evaluation of miR-126 and miR-335-5p expression in salivary glands of patients with pSS and correlation with salivary cystatin S Since cystatin S has been previously described to be regulated in breast cancer by miR-126 and miR-335-5p [33] , we decided to determine the levels of these two miRNAs in our cohort of patients and to evaluate the were assessed by qPCR in five controls (i.e. idiopathic sicca syndrome), five pSS patients high salivary flow and five with low salivary flow. We chose to investigate the expression of those miRNAs in pSS with the same focus score (>3) but different salivary flow rates in order to eliminate any possible difference due to the presence of B cell infiltration. We found that the expression levels of miR-126 and miR-335-5p in our cohort increased significantly in inverse proportion with salivary flow (Fig. 5A and  B) .
To evaluate whether miR-126 and miR-335-5p regulate cystatin S expression, degrading or inhibiting the cystatin S mRNA, we assessed the mRNA level in pSS salivary glands (Fig. 5C ). In the cohort chosen, the mRNA of cystatin S (normalized for GAPDH) did not change significantly, suggesting inhibition of its translation rather than mRNA degradation.
Discussion
In this study we demonstrated that the expression of salivary cystatin S was reduced in patients with pSS with respect to HVs, especially in those patients with a lower salivary flow rate and more evident involvement of the submandibular glands. The novelty of this study relies on several aspects. First, it represents an attempt to translate information derived from advanced omics techniques into clinical practice. It is widely recognized that these novel technologies generate panels of potential biomarkers that need to be validated and traceable by less expensive analytic techniques in order to be transferred in daily care or in clinical trials. In fact, we decided to detect cystatin S in pSS whole saliva in a semi-quantitative way, taking into account its role in oral immunity [24, 34] , but especially considering that this protein had been found to decrease in the saliva of pSS patients in our and other laboratories [2123] .
More specifically, we found that cystatin S correlated positively with patients' USFR and that cystatin S variation
FIG. 4 Cystatin S expression in pSS patients according to SGUS findings
Column scatter graphs show cystatin S levels in pSS patients subdivided according to the US findings in their (A) submandibular or (B) parotid glands. Cystatin S was significantly reduced in patients with a predominant involvement of submandibular glands (P < 0.0001). ***P < 0.001.
FIG. 3
Correlation between the change in cystatin S and unstimulated salivary flow rate over the follow-up period Scatter plot displays the relationship between the change in cystatin S (y-axis) and USFR (x-axis) in five pSS patients followed over time. A strong positive correlation was observed (r = 0.751, P = 0.02). Á: change in; Cys-s: cystatin S.
FIG. 2 Correlation between cystatin S and unstimulated salivary flow rate in pSS patients
Scatter plot shows the relationship between cystatin S (y-axis) and USFR (x-axis) in patients with pSS and a high focus score (>3). A strong positive correlation was observed (r = 0.751, P = 0.02).
www.rheumatology.oxfordjournals.org significantly correlated with changes in patients' USFR over time. Since only five patients were monitored in this study, these data need to be validated in a larger cohort. However, our observations appear of particular interest since cystatin S seems to be able to reflect salivary gland dysfunction. Moreover, it is of interest that cystatin S is secreted mainly by submandibular glands and that whole saliva largely mirrors the contents of submandibular/sublingual secretions rather than parotid secretions [25] . In fact, submandibular and parotid gland flow rates were not individually determined. However, since the unstimulated whole salivary flow is mainly represented by the submandibular flow rather than the parotid, we speculated that cystatin S reduction may reflect submandibular gland dysfunction [35] . Several studies have demonstrated that involvement of submandibular glands occurs quite early in pSS onset, often before parotid involvement [36, 37] . More specifically, Pijpe et al. [26] demonstrated that in early pSS the submandibular flow rate decreases more markedly than the parotid flow rate.
All patients enrolled in our study had an established pSS diagnosis, therefore we were unable to analyse the relationship between cystatin S and disease duration and its value as a diagnostic biomarker in the early stages of the disease. However, when we evaluated the correlation between the expression of cystatin S and the presence of pathological findings in submandibular glands and/or parotid glands, we observed that cystatin S was significantly lower in those patients with a higher ultrasonography score in the submandibular glands. The number of pSS patients enrolled in this study was relatively small to talk about subgroups, however, the correlation between cystatin S and submandibular ultrasonographic involvement led us to speculate that, once validated, cystatin S might be potentially useful to identify a specific subset of patients at greater risk of more prominent glandular dysfunction during the subsequent follow-up and to facilitate early diagnosis of pSS.
Another strength of this study is represented by the evaluation of the potential genetic influence on cystatin S aberrant expression. Indeed, in MSG biopsies of patients with pSS, we found an upregulation of miR-335-5p and miR-126 that resulted significantly higher in those patients with lower unstimulated salivary flow. These miRNAs have been linked to several types of cancer, including lung and breast cancers, and their upregulation seems to simultaneously inhibit invasiveness and promote apoptosis of cancer cells [3841] . Intriguingly, miR-335-5p and miR-126 have been linked to the CST4 gene. We therefore speculated that the downregulation of cystatin S might be influenced by an upregulation of miR-335-5p and miR-126 [33] . Since cystatin S transcripts were not differently expressed in patients with lower and higher salivary flow rates, we hypothesized that miRNAs may inhibit cystatin mRNA translation rather than promote mRNA degradation. From this perspective, our study represents a preliminary attempt to combine omics complementary data to clarify the pathogenetic pathways underlying the different subsets of pSS, leading to new evidence supporting the development of concepts for curative therapies.
In order to be translated and adopted into clinical practice, these observations should be replicated in larger studies. In fact, in this study we did not include patients with   FIG. 5 miR-335-5p, miR-126 and salivary cystatin S levels in pSS subgroups vs HVs Expression levels of mature (A) miR-126, (B) miR-335-5p and (C) cystatin S mRNA were determined by real-time qPCR. Values were normalized to U6 or GAPDH levels, respectively, and expressed as the fold increase over controls. CST: salivary cystatin S. *P < 0.05, **P < 0.01.
other systemic disorders, such as sarcoidosis, IgG4-related disease or lymphoma, that may have an influence on salivary cystatin S levels. However, on the basis of these results, salivary cystatin S seems to represent a promising candidate for distinguishing between the different subsets of the disease.
